| Glecaprevir–pibrentasvir for 8 or 12 weeks in HCV genotype 1 or 3 infection S Zeuzem, GR Foster, S Wang, A Asatryan, E Gane, JJ Feld, T Asselah, ... New England Journal of Medicine 378 (4), 354-369, 2018 | 485 | 2018 |
| Sustained virologic response of 100% in HCV genotype 1b patients with cirrhosis receiving ombitasvir/paritaprevir/r and dasabuvir for 12 weeks JJ Feld, C Moreno, R Trinh, E Tam, S Bourgeois, Y Horsmans, ... Journal of hepatology 64 (2), 301-307, 2016 | 249 | 2016 |
| Engagement in social activities and progression from mild to severe cognitive impairment: the MYHAT study TF Hughes, JD Flatt, B Fu, CCH Chang, M Ganguli International psychogeriatrics 25 (4), 587-595, 2013 | 184 | 2013 |
| Mild cognitive impairment: incidence and vascular risk factors in a population-based cohort M Ganguli, B Fu, BE Snitz, TF Hughes, CCH Chang Neurology 80 (23), 2112-2120, 2013 | 181 | 2013 |
| Efficacy and safety of glecaprevir/pibrentasvir in Japanese patients with chronic genotype 2 hepatitis C virus infection H Toyoda, K Chayama, F Suzuki, K Sato, T Atarashi, T Watanabe, ... Hepatology 67 (2), 505-513, 2018 | 131 | 2018 |
| Interactive video gaming compared with health education in older adults with mild cognitive impairment: a feasibility study TF Hughes, JD Flatt, B Fu, MA Butters, CCH Chang, M Ganguli International journal of geriatric psychiatry 29 (9), 890-898, 2014 | 113 | 2014 |
| Integrated resistance analysis of CERTAIN-1 and CERTAIN-2 studies in hepatitis C virus-infected patients receiving glecaprevir and pibrentasvir in Japan P Krishnan, G Schnell, R Tripathi, J Beyer, T Reisch, T Dekhtyar, M Irvin, ... Antimicrobial agents and chemotherapy 62 (2), 10.1128/aac. 02217-17, 2018 | 58 | 2018 |
| Vascular risk factors and cognitive decline in a population sample M Ganguli, B Fu, BE Snitz, FW Unverzagt, DA Loewenstein, TF Hughes, ... Alzheimer Disease & Associated Disorders 28 (1), 9-15, 2014 | 51 | 2014 |
| Myocardial damage detected by late gadolinium enhancement cardiovascular magnetic resonance is associated with subsequent hospitalization for heart failure TC Wong, KM Piehler, KM Zareba, K Lin, A Phrampus, A Patel, JC Moon, ... Journal of the American Heart Association 2 (6), e000416, 2013 | 50 | 2013 |
| Old worries and new anxieties: behavioral symptoms and mild cognitive impairment in a population study C Andreescu, E Teverovsky, B Fu, TF Hughes, CCH Chang, M Ganguli The American Journal of Geriatric Psychiatry 22 (3), 274-284, 2014 | 41 | 2014 |
| ENDURANCE-1: efficacy and safety of 8-versus 12-week treatment with ABT-493/ABT-530 in patients with chronic HCV genotype 1 infection S Zeuzem, JJ Feld, S Wang, M Bourliere, H Wedemeyer, EJ Gane, ... Hepatology 64, 132A-133A, 2016 | 39 | 2016 |
| Prediction of remission and low disease activity in disease-modifying anti-rheumatic drug-refractory patients with rheumatoid arthritis treated with golimumab N Vastesaeger, AG Kutzbach, H Amital, K Pavelka, MA Lazaro, RJ Moots, ... Rheumatology 55 (8), 1466-1476, 2016 | 36 | 2016 |
| Ombitasvir/paritaprevir/r, dasabuvir, and sofosbuvir treatment of patients with HCV genotype-infection who failed a prior course of DAA therapy: the quartz-I study F Poordad, M Bennett, TE Sepe, E Cohen, RW Reindollar, G Everson, ... Journal of hepatology 2 (64), S767-S768, 2016 | 33 | 2016 |
| Progesterone level at oocyte retrieval predicts in vitro fertilization success in a short-antagonist protocol: a prospective cohort study S Nayak, ME Ochalski, B Fu, KM Wakim, TJ Chu, X Dong, AN Wakim Fertility and sterility 101 (3), 676-682. e1, 2014 | 30 | 2014 |
| Overview of multiple testing methodology and recent development in clinical trials D Wang, Y Li, X Wang, X Liu, B Fu, Y Lin, L Larsen, W Offen Contemporary clinical trials 45, 13-20, 2015 | 27 | 2015 |
| Accuracy of the Berger-Exner test for detecting third-order selection bias in randomised controlled trials: a simulation-based investigation S Mickenautsch, B Fu, S Gudehithlu, VW Berger BMC Medical Research Methodology, 2014 | 26 | 2014 |
| Turquoise-III: safety and efficacy of 12-week ribavirin-free treatment for patients with HCV genotype 1b and cirrhosis JJ Feld, C Moreno, R Trinh, E Tam, S Bourgeois, Y Horsmans, ... Journal of Viral Hepatitis 22, 135-135, 2015 | 19 | 2015 |
| ENDURANCE-1: a phase 3 evaluation of the efficacy and safety of 8-versus 12-week treatment with glecaprevir/pibrentasvir (formerly ABT-493/ABT-530) in HCV genotype 1 infected … S Zeuzem, J Feld, S Wang, M Bourlière, H Wedemeyer, EJ Gane, ... vitro 1, 2, 2016 | 18 | 2016 |
| Retreatment of HCV genotype 1 DAA-failures with ombitasvir/paritaprevir/r, dasabuvir, and sofosbuvir F Poordad, M Bennett, TE Sepe, E Cohen, R Reindollar, GT Everson, ... Hepatology 62 (6), 1392A-1392A, 2015 | 18 | 2015 |
| High antiviral activity of NS 5A inhibitor ABT‐530 with paritaprevir/ritonavir and ribavirin against hepatitis C virus genotype 3 infection F Poordad, CS Landis, A Asatryan, DF Jackson III, TI Ng, B Fu, CW Lin, ... Liver International 36 (8), 1125-1132, 2016 | 14 | 2016 |